Department of Cardiology, Epworth Healthcare, Melbourne, 3121 Victoria, Australia.
Department of Respiratory Medicine, Epworth Healthcare, Melbourne, 3121 Victoria, Australia.
Rev Cardiovasc Med. 2021 Mar 30;22(1):181-184. doi: 10.31083/j.rcm.2021.01.267.
Amiodarone is a common antiarrhythmic drug that is utilised in clinical practice and is associated with pulmonary toxicity. The most common form of pulmonary complication is interstitial pneumonitis which is treated with discontinuation of amiodarone and initiation of corticosteroids. Amiodarone-induced pulmonary eosinophilia is a rare complication of amiodarone therapy, with blood and pulmonary eosinophilia the predominant features. During the COVID-19 era, the incidence of delay in treatment of pulmonary pathology is also delayed due to the effort of excluding COVID-19 infection. Here we report a case of a 64-year-old man who developed eosinophilic pneumonia after initiation of amiodarone therapy, and the investigations required to exclude other forms of pulmonary toxicity. We also reviewed the effect of COVID-19 testing in the management of patients presenting with respiratory distress.
胺碘酮是一种常用的抗心律失常药物，在临床实践中应用广泛，与肺毒性相关。最常见的肺部并发症是间质性肺炎，其治疗方法是停用胺碘酮并开始使用皮质类固醇。胺碘酮诱导的肺嗜酸性粒细胞增多症是胺碘酮治疗的罕见并发症，以血液和肺部嗜酸性粒细胞增多为主要特征。在 COVID-19 时代，由于排除 COVID-19 感染的努力，肺病理学治疗的延迟也随之延迟。在这里，我们报告了一例 64 岁男性在开始胺碘酮治疗后发生嗜酸性肺炎的病例，以及排除其他形式的肺毒性所需的检查。我们还回顾了 COVID-19 检测在处理出现呼吸窘迫的患者中的作用。
